Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
September 5, 2019updated 03 Oct 2019 1:36pm

Esperion’s cholesterol-lowering drug has positive Phase II results for Type 2 diabetes patients

The drug combination was shown to significantly lower LDL-C by 40% compared to placebo and reduce high-sensitivity C-reactive protein.

By GlobalData Healthcare

Espiron’s Phase II trial of their cholesterol-lowering bempedoic acid + ezetimibe combination drug in patients with type 2 diabetes has met its primary endpoint and key secondary endpoints after a 12-week study.

The drug combination was shown to significantly lower LDL-C by 40% compared to placebo and reduce high-sensitivity C-reactive protein (hsCRP), an important marker of inflammation associated with cardiovascular disease, by 25%. There was no worsening of glycemic control.

The Phase II double-blind, parallel-group study enrolled 179 high cholesterol diabetic patients who were randomized to receive either the bempedoic acid + ezetimibe combination tablet, ezetimibe, or placebo. Patients enrolled were on stable background diabetes medications and washed out of lipid-modifying therapies. Safety and tolerability of the bempedoic acid/ezetimibe combination tablet over 12 weeks results showed no clinical differences between the bempedoic acid + ezetimibe combination tablet, placebo, and ezetimibe patient groups in the occurrence of adverse events.

This was an important outcome, as patients with both high cholesterol and type 2 diabetes pose a treatment challenge. Statins are usually used as the primary cholesterol-lowering drug, but they have been linked to increased blood sugar levels. Esperion’s combination drug could help eliminate these risks for Type 2 diabetes patients.

Bempedoic acid in combination with ezetimibe and as a monotherapy is awaiting approval by the US Food and Drug Administration, and has a PDUFA date of February 2020.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU